BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21954796)

  • 1. The case of the tingling toes.
    Eisenberg S
    ONS Connect; 2011 Sep; 26(9):17. PubMed ID: 21954796
    [No Abstract]   [Full Text] [Related]  

  • 2. Peripheral neuropathy induced by oxaliplatin-based chemotherapy.
    J Support Oncol; 2006 Feb; 4(2):82-3. PubMed ID: 16499128
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement.
    Dunlap B; Paice JA
    J Support Oncol; 2006 Sep; 4(8):398-9. PubMed ID: 17004514
    [No Abstract]   [Full Text] [Related]  

  • 4. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy.
    Argyriou AA; Antonacopoulou AG; Scopa CD; Kottorou A; Kominea A; Peroukides S; Kalofonos HP
    Oncology; 2009; 77(3-4):254-6. PubMed ID: 19738391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.
    Tofthagen C; McAllister RD; McMillan SC
    Clin J Oncol Nurs; 2011 Apr; 15(2):182-8. PubMed ID: 21444285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.
    Basso M; Modoni A; Spada D; Cassano A; Schinzari G; Lo Monaco M; Quaranta D; Tonali PA; Barone C
    Cancer Chemother Pharmacol; 2011 May; 67(5):1179-87. PubMed ID: 20872144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
    Argyriou AA; Chroni E; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP
    Neurology; 2006 Dec; 67(12):2253-5. PubMed ID: 17190958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral sensory neuropathy--fighting cold with cold.
    Castro M
    Lancet Oncol; 2008 May; 9(5):415-6. PubMed ID: 18452855
    [No Abstract]   [Full Text] [Related]  

  • 9. The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?
    Park SB; Lin CS; Krishnan AV; Kiernan MC
    Cancer Chemother Pharmacol; 2011 May; 67(5):1189-90; author reply 1191-2. PubMed ID: 21327679
    [No Abstract]   [Full Text] [Related]  

  • 10. [Platinum drugs].
    Kusaba H; Baba E
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():143-5. PubMed ID: 25831739
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy-induced peripheral neuropathy: the end of the beginning?
    Krishnan AV; Park SB
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):359. PubMed ID: 23833264
    [No Abstract]   [Full Text] [Related]  

  • 12. [Peripheral Nerve Toxicity Caused by Oxaliplatin: Research Progress of Integrative Medicine].
    Zhang D; Yang YF
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Aug; 35(8):1022-4. PubMed ID: 26485922
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistent neuropathy after treatment with cisplatin and oxaliplatin.
    Brouwers EE; Huitema AD; Boogerd W; Beijnen JH; Schellens JH
    Acta Oncol; 2009; 48(6):832-41. PubMed ID: 19308757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system.
    Binder A; Stengel M; Maag R; Wasner G; Schoch R; Moosig F; Schommer B; Baron R
    Eur J Cancer; 2007 Dec; 43(18):2658-63. PubMed ID: 17855072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of platinum-induced neuropathy should be based on both objective and subjective examinations.
    Oldenburg J; Fosså SD
    Acta Oncol; 2009; 48(6):804-6. PubMed ID: 19484592
    [No Abstract]   [Full Text] [Related]  

  • 16. Peripheral neuropathy: experimental findings, clinical approaches.
    J Support Oncol; 2007 Feb; 5(2):61-3. PubMed ID: 17354318
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy.
    Hohmann AG
    Pain; 2005 Nov; 118(1-2):3-5. PubMed ID: 16203094
    [No Abstract]   [Full Text] [Related]  

  • 19. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
    Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
    Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ABCB1 polymorphisms in patients with Charcot-Marie-Tooth disease. A possible relationship with neurotoxicity due to cytostatic treatment].
    de la Haba-Rodríguez JR; Ortiz-Morales MJ; Gómez-España MA; Aranda Aguilar E
    Med Clin (Barc); 2012 Apr; 138(10):456-7. PubMed ID: 21982686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.